Advertisement

Early serum HBV RNA combined with HBsAg response can predict HBeAg seroconversation in patients on Entecavir therapy (ClinicalTrials.gov (NCT03909191))

Published:January 31, 2022DOI:https://doi.org/10.1016/j.jinf.2022.01.035
      hepatits B virus
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wu Y.
        • Wen J.
        • Tang G.
        • Zhang J.
        • Xin J.
        On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B.
        J Infect. 2021; 83 (NovPubMed PMID: 34474058. Epub 2021/09/03): 594-600
      1. N.A. Terrault, N.H. Bzowej, K.-M. Chang, J.P. Hwang, M.M. Jonas, Murad6 M.H. AASLD Guidelines for Treatment of Chronic Hepatitis B. 2015.

        • Liu Y.
        • Xue J.
        • Liao W.
        • Yan H.
        • Liang X.
        Serum HBV RNA Dynamic and Drug Withdrawal Predictor Value in Patients With Chronic HBV Infection on Long-term Nucleos(t)ide Analogue (NA) Therapy.
        J Clin Gastroenterol. 2020; 54 (SepPubMed PMID: 32604147. Pubmed Central PMCID: PMC7458089. Epub 2020/07/01): e73-e82
        • Wang X.
        • Wang Z.
        • Chi X.
        • Wu R.
        • Jin Q.
        • Xu H.
        • et al.
        Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks.
        Int J Infect Dis. 2020; 99 (OctPubMed PMID: 32721532. Epub 2020/07/30): 171-178
        • van Bommel F.
        • van Bommel A.
        • Krauel A.
        • Wat C.
        • Pavlovic V.
        • Yang L.
        • et al.
        Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B.
        J Infect Dis. 2018; 218 (Aug 24PubMed PMID: 29741634. Epub 2018/05/10): 1066-1074
        • Jia W.
        • Zhu M.Q.
        • Xun QiQ.
        • Ting Wan.g
        • Xiao W.en
        • Chen Pe.i D.ong
        • et al.
        Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a.
        Virology J. 2019; 16: 61
        • Liu Y.
        • Jiang M.
        • Xue J.
        • Yan H.
        • Liang X.
        Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection.
        BMC Gastroenterol. 2019; 19 (Apr 16PubMed PMID: 30991954. Pubmed Central PMCID: PMC6469196. Epub 2019/04/18): 53
        • Luo H.
        • Zhang X.X.
        • Cao L.H.
        • Tan N.
        • Kang Q.
        • Xi H.L.
        • et al.
        Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients.
        World J Gastroenterol. 2019; 25 (Feb 14PubMed PMID: 30783375. Pubmed Central PMCID: PMC6378541. Epub 2019/02/21): 719-728
        • Liu S.
        • Zhou B.
        • Valdes J.D.
        • Sun J.
        • Guo H.
        Serum Hepatitis B Virus RNA: a New Potential Biomarker for Chronic Hepatitis B Virus Infection.
        Hepatology. 2019; 69 (AprPubMed PMID: 30362148. Pubmed Central PMCID: PMC6438723. Epub 2018/10/27): 1816-1827
        • Liu S.
        • Wu Y.
        • Deng R.
        • Shen S.
        • Fan R.
        • Peng J.
        • et al.
        Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients.
        Antiviral Res. 2021; 189 (MayPubMed PMID: 33711337. Epub 2021/03/13)105037